Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL12352425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL1821276 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4522263 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL13362239 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2228590 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL406207 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403819 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5646 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4696703-A2 | NUCLEIC ACID MOLECULES AND USES THEREOF | CureVac SE (DE) | 2026-02-18 | — | — | EP | claimed |
| US-20250340868-A1 | POLYNUCLEOTIDES ENCODING LINKED ANTIGENS AND USES THEREOF | STEMCELL TECHNOLOGIES CANADA INC (CA) | 2025-11-06 | — | — | US | claimed |
| EP-4631970-A2 | NUCLEIC ACID MOLECULES AND USES THEREOF | CureVac SE (DE) | 2025-10-15 | — | — | EP | claimed |
| EP-4561602-A1 | POLYNUCLEOTIDES ENCODING LINKED ANTIGENS AND USES THEREOF | Stemcell Technologies Canada Inc. (CA) | 2025-06-04 | — | — | EP | claimed |
| US-20250152737-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2025-05-15 | — | — | US | claimed |
| CN-119866224-A | Polynucleotide encoding a linking antigen and uses thereof | 加拿大干细胞技术公司 | 2025-04-22 | — | — | CN | claimed |
| US-20250115916-A1 | MODULATION OF SUV39H1 EXPRESSION BY RNAS | MNEMO THERAPEUTICS (FR) | 2025-04-10 | — | — | US | claimed |
| EP-4514328-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | Strand Therapeutics Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-20110027883-A1 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-02-03 | — | — | US | claimed |
| US-20100292456-A1 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-11-18 | — | — | US | claimed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | claimed |
| WO-2010056795-A1 | NOVEL SYNTHETIC DINUCLEOSIDE POLYPHOSPHATE ANALOGS AND THEIR USE AS NEW THERAPEUTIC AND/OR DIAGNOSTIC MODALITIES | ZATA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-1917006-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT Patent & Licence Trading Ltd. (GB) | 2008-05-07 | — | — | EP | claimed |
| WO-2006136454-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD. (GB) | 2006-12-28 | — | — | WO | claimed |
| EP-1230398-B1 | COLOUR LABELLED OLIGONUCLEOTIDE FOR LABELLING A NUCLEIC ACID MOLECULE | ATTO TEC GMBH (DE) | 2004-06-30 | — | — | EP | claimed |
| US-6713623-B2 | USEFUL AS INTERMEDIATES IN THE SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS | PHARMASSET, LTD. | 2004-03-30 | — | — | US | claimed |
| EP-1230398-A1 | COLOUR LABELLED OLIGONUCLEOTIDE FOR LABELLING A NUCLEIC ACID MOLECULE | Atto-tec GmbH (DE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001036668-A1 | COLOUR LABELLED OLIGONUCLEOTIDE FOR LABELLING A NUCLEIC ACID MOLECULE | ATTO-TEC GMBH (DE) | 2001-05-25 | — | — | WO | claimed |